- Priority Review designation is granted to applications for drugs that, if approved, would be a significant improvement in the safety or effectiveness of treating a serious condition - - Veligrotug ...

Investing.com - Goldman Sachs has reiterated a Buy rating on Viridian Therapeutic (NASDAQ:VRDN) stock with a price target of $40.00. This target represents a 24.5% upside from the current price of $32 ...

Goldman Sachs has reiterated its Buy rating on Viridian Therapeutics stock with a price target of $40.00, anticipating the potential for a mid-2026 launch. William Blair initiated coverage on Viridian ...

In a report released on December 18, Laura Chico from Wedbush maintained a Buy rating on Viridian Therapeutics, with a price target of $47.00. The company’s shares closed last Friday at $31.60.

Fintel reports that on December 23, 2025, Needham maintained coverage of Viridian Therapeutics (NasdaqCM:VRDN) with a Buy recommendation. Analyst Price Forecast Suggests 21.92% Upside As of December ...

Evercore ISI analyst Gavin Clark-Gartner maintained a Buy rating on Viridian Therapeutics yesterday and set a price target of $42.00. Clark-Gartner covers the Healthcare sector, focusing on stocks ...

Please provide your email address to receive an email when new articles are posted on . The FDA granted priority review to veligrotug for the treatment of thyroid eye disease, according to a press ...

The Montreal Carabins dump water on head coach Marco Iadeluca after defeating the University of Saskatchewan Huskies in the 2025 Vanier Cup championship at Mosaic Stadium on Nov. 22, 2025 in Regina.

This article is brought to you by our exclusive subscriber partnership with our sister title USA Today, and has been written by our American colleagues. It does not necessarily reflect the view of The ...

As you read this, farmers Manuel and Leslie Recio are probably in Spain—sampling Tempranillo in Catalonia, learning traditional recipes in Andalucía, or deep in a conversation about growing techniques ...

Viridian Therapeutics (VRDN) announced that the FDA has accepted the biologics license application for veligrotug for the treatment of thyroid eye disease. The application has been granted priority ...